Johnson and Johnson – Page 3

Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years

10 months ago talkbio0Tagged Capacity, development aspects, Drug Industry, Investments, Italy, Johnson and Johnson, Manufacture, research, Upgrade

Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry

Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial

11 months ago talkbio0Tagged Johnson and Johnson, Major Depressive Disorder, Mental Depression, Neuroscience discipline, Phase 3 trial, Seltorexant, Sleeplessness, Symptoms aspect

Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment

Johnson & Johnson Expands Dermatology Portfolio with $850M Acquisition of Proteologix

11 months ago talkbio0Tagged Acquisition (action), bispecifics, Dermatitis, Atopic, J&J, Johnson and Johnson, Proteologix

Johnson & Johnson, J&J, Proteologix, atopic dermatitis, bispecifics, pipeline, acquisition, $850M

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

11 months ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer

12 months ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, Clinical Data, Fibroblast Growth Factor Receptors, Inhibitor, Johnson and Johnson, Malignant neoplasm of urinary bladder

Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.

Contineum Launches IPO Campaign to Accelerate Multiple Sclerosis Pipeline

1 year ago talkbio0Tagged Backed, Contineum, IPO, Johnson and Johnson, Multiple Sclerosis, Phase 2 Clinical Trials, PIPE-307, Public Offering

Contineum Therapeutics, Initial Public Offering (IPO), Johnson & Johnson (J&J) Backed, Multiple Sclerosis (MS) Pipeline, Phase II Trial, PIPE-307

J&J Scores First-Line Approval for Rybrevant Combination in Lung Cancer with EGFR Exon 20 Mutations

1 year ago talkbio0Tagged amivantamab-vmjw, Approved, carboplatin-pemetrexed chemotherapy, Disease Progression, EGFR Exon 20, first-line, Insertion Mutation, Johnson and Johnson, Mortality Risk, Non-Small Cell Lung Carcinoma, Objective Response Rate, ORR, Progression-Free Survival, Reduced, Rybrevant, United States Food and Drug Administration

Johnson & Johnson, Rybrevant (amivantamab-vmjw), FDA Approval, First-Line Treatment, Non-Small Cell Lung Cancer (NSCLC), EGFR Exon 20 Insertion Mutations, Carboplatin-Pemetrexed Chemotherapy, Phase 3 PAPILLON Study, Reduced Disease Progression or Mortality Risk, Improved Objective Response Rate (ORR) and Progression-Free Survival (PFS)